Have we realised the full potential of S1P receptor modulation in MS?

Saturday 19 June 2021, 12:15–13:15 CEST
Janssen symposium at the European Academy of Neurology (EAN) congress

Please join us for this Janssen-sponsored symposium which will focus on the role of S1P receptor modulators and how they fit into the treatment landscape of multiple sclerosis (MS). During this symposium, you will have the opportunity to join the debate around how S1P receptor modulators fit into the changing MS treatment landscape, along with hearing discussions around the clinical evidence that supports their therapeutic potential. We will also explore the patient’s perspective to determine ways of aligning patient and clinician treatment goals and options for monitoring disease worsening. Lastly, we will assess the impact of the COVID-19 pandemic on future clinical practice. We hope that you can join us for what promises to be an engaging and informative symposium.

Please note that this programme has been accredited by the European Accreditation Committee in CNS (EACIC) for one Continuing Medical Education (CME) credit.

Faculty

Dr Mar Tintoré  
Scientific Committee  
Chief of Neurology, Neurology-Neuroimmunology Department, Multiple Sclerosis Centre of Catalonia (Cemcat), Hospital Vall d’Hebron, Barcelona, Spain

Professor Frauke Zipp  
Scientific Committee  
Professor of Neurology and Neuroimmunology, Rhine-Main-Neuroscience Network, Director, Department of Neurology, University Medical Center, Johannes Gutenberg University Mainz, Mainz, Germany

Professor Fred Lublin  
Speaker  
Saunders Family Professor of Neurology, Director of the Corinne Goldsmith Dickinson Center for Multiple Sclerosis, Mount Sinai Medical Center, New York, US

Agenda

12:15 Welcome and introduction  
Professor Frauke Zipp and Dr Mar Tintoré

12:18 Now and beyond: where are we heading in the treatment of MS?  
Professor Frauke Zipp

12:31 What matters most to patients?  
Professor Fred Lublin

12:44 Safety of S1P receptor modulation in the COVID-19 era  
Dr Mar Tintoré

12:57 What challenges do we face in the treatment of MS? Your questions answered  
Professor Frauke Zipp, Dr Mar Tintoré and Professor Fred Lublin

13:12 Closing statements  
Professor Frauke Zipp and Dr Mar Tintoré